Literature DB >> 7489250

Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries.

H Ueno1, J J Li, H Tomita, H Yamamoto, Y Pan, Y Kanegae, I Saito, A Takeshita.   

Abstract

We quantitatively evaluated the effectiveness of a repeat administration of a recombinant adenoviral vector expressing bacterial Escherichia coli lacZ into the same arterial site of a relatively large animal, the dog. The replication-defective adenoviral vector was introduced percutaneously into balloon-injured femoral arteries through a double-balloon catheter. After a single dose of adenoviral vector, up to 90% of surface (73 +/- 16%, n = 7) and smooth muscle cells in multiple layers of the media showed transgene expression as evaluated by 5-bromo-4-chloro-3-indoyl beta-D-galactopyranoside histostaining without extralocal expression, as assessed by polymerase chain reaction. High-level expression (measured as beta-galactosidase activity) peaked 7 days after transfer and was transient, although it was retained for a month. Second does of the same adenovirus to the same arterial site were given 1, 2, 5, or 8 weeks after the first administration. At 1 week the second dose significantly enhanced lacZ expression. At 2, 5, or 8 weeks the second dose reinduced lacZ expression at 25% to 30% of the full expression. lacZ expression was also detected in preimmuned dogs, although the expression levels correlated inversely to the titer of neutralizing antibodies in their serum. These results demonstrate that arterial gene expression can be enhanced by a second administration of the same adenovirus after a short interval and that a repeat dose after a long interval partially but significantly reinduces gene expression despite the presence of an immune response. These data may provide an additional scientific foundation for the use of adenovirus-mediated arterial gene transfer in future clinical practice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489250     DOI: 10.1161/01.atv.15.12.2246

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo.

Authors:  H Ooboshi; C D Ríos; D D Heistad
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

2.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

3.  Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat.

Authors:  Z Qi; N Atsuchi; A Ooshima; A Takeshita; H Ueno
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer.

Authors:  Yasuo Okada; Hikaru Ueno; Masataka Katagiri; Takahiro Oneyama; Kana Shimomura; Satoshi Sakurai; Izumi Mataga; Michiko Moride; Hitoshi Hasegawa
Journal:  Odontology       Date:  2010-02-16       Impact factor: 2.634

6.  Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity.

Authors:  A H Schulick; G Vassalli; P F Dunn; G Dong; J J Rade; C Zamarron; D A Dichek
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.